Medtronic buys new spinal cord tech to boost pain therapies unit

Amid a broader slowdown in the spinal cord stimulation market, Medtronic is acquiring technology from Stimgenics that offers a new way of programming its Intellis implant.

By Maria Rachal • Jan. 9, 2020

Digital health M&A flatlines in 2019, but IPO activity promising

Rock Health sees creation of remote patient monitoring reimbursement codes, progress on data blocking rules and FDA's Pre-Cert program as potential growth catalysts for the sector.

By Nick Paul Taylor • Jan. 8, 2020

OrthoPediatrics sells Vilex assets in preparation for more M&A

The device maker sold the adult piece of the Vilex business, which it acquired last year, for $25 million.

By Nick Paul Taylor • Jan. 7, 2020

Illumina scraps $1.2B PacBio takeover amid regulatory pushback

Cowen analysts listed Agilent, Danaher and Thermo Fisher as potential buyers of Pacific Biosciences.

By Nick Paul Taylor • Jan. 3, 2020

FTC slaps Stryker, Wright Medical with second request

In a second amendment to its tender offer statement for Wright Medical, Stryker acknowledged a Wright shareholder's class action lawsuit alleging Wright's solicitation statement was false and misleading.

By David Lim , Maria Rachal • Updated Jan. 23, 2020

Wright Medical filings, report hint of rivals to Stryker's $5.4B acquisition

Regulatory filings show as many as five parties besides Stryker, which agreed to pay $30.75 per share, were interested in bidding for Wright.

By Maria Rachal • Dec. 20, 2019

J&J takes over Verb Surgical as Verily exits robotics partnership

The move comes four years after J&J launched the venture with Google-backed Verily, further signaling the medtech giant's play for the digital surgery market after its $3.4 billion acquisition of Auris Health.

By Maria Rachal • Dec. 20, 2019

Delaware court deals blow to Boston Scientific in Channel Medsystems lawsuit

Boston Scientific's attempt to terminate its $275 million acquisition of cryoablation device maker Channel Medsystems was ruled inappropriate by the Delaware Court of Chancery Wednesday. 

By David Lim • Dec. 19, 2019

Fujifilm announces delay to $1.63B buyout of Hitachi's diagnostic imaging arm

Citing COVID-19's impacts as a source of slowdown, Fujifilm said the deal is no longer expected to close in July.

By Maria Rachal • Updated May 28, 2020

FTC seeks to block Illumina's $1.2B PacBio acquisition over monopoly concerns

Illumina announced Wednesday it will extend the end time of its merger plan with PacBio to March 31, 2020.

By David Lim • Updated Dec. 19, 2019

Medtronic acquires meal detection tech to bolster personalized closed loop system

Klue's fine motor artificial intelligence software that can sense eating will help future diabetes management systems become hands free, the company said.

By Maria Rachal • Dec. 18, 2019

The MedTech Dive Awards of 2019

From TAVR's takeoff to FDA's new approaches to premarket review, these are the industry forces that left their mark on medical technology this year.

Dec. 9, 2019

Baxter closes $350M acquisition of Sanofi's Seprafilm adhesion barrier

The company said it will immediately begin integrating the product, meant to reduce adhesion barriers in patients having abdominal or pelvic laparotomy procedures, into its advanced surgery business.

By Maria Rachal • Updated Feb. 18, 2020

Hologic unloads underperforming Cynosure medical aesthetics unit

"This divestiture was a long time coming and puts an end to a bad marriage," William Blair analyst Brian Weinstein said of Hologic's $1.6 billion deal in 2017. Now, the company expects $138 million in cash proceeds from its sale.

By Dana Elfin • Updated Dec. 30, 2019

Asian private equity group to buy Lumenis in $1B deal

The maker of minimally invasive devices used in aesthetic procedures competes with rivals like Candela Medical.

By Nick Paul Taylor • Nov. 20, 2019

Wright Medical growth slowed in run-up to Stryker deal

While Wright's Cartiva big toe treatment dragged on sales for a second straight quarter, Stryker expects the acquisition to bolster its broader extremities business, particularly in shoulder devices.

By Susan Kelly • Nov. 11, 2019

Exact Sciences closes Genomic Health deal, wins breakthrough tag for liver cancer blood test

The Cologuard maker said it intends to roll out the test for hepatocellular carcinoma in the second half of 2020.

By Maria Rachal • Nov. 8, 2019

Paclitaxel, foreign exchange among drags on BD's Q4

Still, executives are optimistic about integration of the 2017 acquisition of Bard, set to deliver $100 million in projected fiscal 2020 savings.

By David Lim • Nov. 5, 2019

Stryker goes to extrem(iti)es in $4B Wright Medical takeout

Worth $5.4 billion including debt, the deal dwarfs the K2M buyout and sent shares in extremities device maker Wright Medical soaring almost 30%.

By Maria Rachal • Updated Nov. 4, 2019

Exact Sciences Q3 revenue jumps 85% but Cologuard orders disappoint

Shares in the non-invasive colon cancer test manufacturer fell approximately 6% Wednesday. Exact plans to focus on increasing payer coverage of Cologuard and communicating its label expansion to doctors.

By David Lim • Oct. 30, 2019

UK regulator mulls blocking Illumina's $1.2B PacBio takeover

The watchdog said the union "would result in a significant reduction of competition," leading some analysts to predict the deal won't go through.

By Nick Paul Taylor • Oct. 25, 2019

Merged GTX medical seeks broader footprint in spinal cord stim market

GTX hopes to start clinical studies of an implantable spinal cord stimulation system during 2021, CEO Sjaak Decker told MedTech Dive.

By Dana Elfin • Updated Oct. 22, 2019

Abbott 'working through a handful of items' with FDA on FreeStyle Libre 2

Third-quarter revenue for the medtech came in at $8.08 billion, slightly below Wall Street expectations, but executives praised the growth of key products FreeStyle Libre, MitraClip and Alinity on its earnings call.

By David Lim • Oct. 16, 2019

Qiagen taps new CEO, restructures in 'clearly a bad day'

The company is also suspending next-generation sequencing-related instrument development as it pivots into a 15-year partnership with Illumina to develop in vitro diagnostic kits.

By David Lim • Oct. 8, 2019

Lantheus strikes deal to buy Progenics, sparking investor backlash

Velan Capital, a big shareholder in Progenics, accused management of selling at a "massive discount" and preventing investors from being heard.

By Nick Paul Taylor • Oct. 3, 2019